83 related articles for article (PubMed ID: 29191581)
41. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Dingemans AM; Mellema WW; Groen HJ; van Wijk A; Burgers SA; Kunst PW; Thunnissen E; Heideman DA; Smit EF
Clin Cancer Res; 2013 Feb; 19(3):743-51. PubMed ID: 23224737
[TBL] [Abstract][Full Text] [Related]
42. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
43. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.
Dai J; Jin G; Dong J; Chen Y; Xu L; Hu Z; Shen H
J Thorac Oncol; 2010 Nov; 5(11):1748-54. PubMed ID: 20881643
[TBL] [Abstract][Full Text] [Related]
44. Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.
Vilmar A; Santoni-Rugiu E; Cillas JG; Huarriz M; Sørensen JB
Anticancer Res; 2014 Jun; 34(6):2991-6. PubMed ID: 24922664
[TBL] [Abstract][Full Text] [Related]
45. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
46. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience.
Kefeli U; Kaya S; Ustaalioglu BO; Bilici A; Kefeli AU; Yildirim ME; Seker M; Yilmaz B; Salepci T; Uygun K; Gumus M
Med Oncol; 2011 Sep; 28(3):661-6. PubMed ID: 20354816
[TBL] [Abstract][Full Text] [Related]
48. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
49. Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
Peng Y; Wang L; Qing Y; Li C; Ren T; Li Q; Li M; Zhang S; Shan J; Wang G; Yang Z; Wang D
Sci Rep; 2015 Dec; 5():17766. PubMed ID: 26656462
[TBL] [Abstract][Full Text] [Related]
50. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy.
Abed A; Calapre L; Lo J; Correia S; Bowyer S; Chopra A; Watson M; Khattak MA; Millward M; Gray ES
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229510
[TBL] [Abstract][Full Text] [Related]
52. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
53. The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer.
Li N; Shao K; Chen Z; Qiu B; Wang Z; Tan F; Wang J; Tan X; Li B; Xiong M; Zhou F; He J
Fam Cancer; 2011 Jun; 10(2):331-6. PubMed ID: 21104151
[TBL] [Abstract][Full Text] [Related]
54. Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small cell lung carcinoma.
Cheng L; Liu Q; Wang M; Gu Y; Wang J; Wei Q; Zhang R
Carcinogenesis; 2020 Sep; 41(9):1203-1212. PubMed ID: 32614429
[TBL] [Abstract][Full Text] [Related]
55. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
Ramnath N; Tan D; Li Q; Hylander BL; Bogner P; Ryes L; Ferrone S
Cancer Immunol Immunother; 2006 Aug; 55(8):891-9. PubMed ID: 16187081
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.
Eberst G; Vernerey D; Laheurte C; Meurisse A; Kaulek V; Cuche L; Jacoulet P; Almotlak H; Lahourcade J; Gainet-Brun M; Fabre E; Le Pimpec-Barthes F; Adotevi O; Westeel V
BMC Cancer; 2022 May; 22(1):529. PubMed ID: 35546670
[TBL] [Abstract][Full Text] [Related]
57. Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?
Unal D; Eroglu C; Tasdemir A; Karaman H; Kurtul N; Oguz A; Goksu SS; Kaplan B
Cancer Res Treat; 2016 Jan; 48(1):98-105. PubMed ID: 25779361
[TBL] [Abstract][Full Text] [Related]
58. HLA-A2 expression, stage, and survival in colorectal cancer.
Kiewe P; Mansmann V; Scheibenbogen C; Buhr HJ; Thiel E; Nagorsen D
Int J Colorectal Dis; 2008 Aug; 23(8):767-72. PubMed ID: 18461337
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcomes of stage-IV non-small-cell lung cancer in young patients and the impact of tumor markers.
Dos Santos PAR; Li Y; Ernani V; D'Cunha J; Aubry MC; Yang P
Cancer Treat Res Commun; 2023; 36():100723. PubMed ID: 37327571
[TBL] [Abstract][Full Text] [Related]
60. Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers.
Gagnon B; Agulnik JS; Gioulbasanis I; Kasymjanova G; Morris D; MacDonald N
Br J Cancer; 2013 Oct; 109(8):2066-71. PubMed ID: 24064979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
